US · BFRIW
Biofrontera Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Woburn, DE 01801
- Website
- biofrontera-us.com
Price · as of 2024-12-31
—
Market cap 791.47K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $353.33 | |||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $19.56 | $0.00 | |||
| 2023 | $0.00 | $0.00 | |||
| 2024 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Biofrontera Inc.'s (BFRIW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BFRIW | Biofrontera Inc. | $0.07 | 791.47K | — | — | — | — | — | — | — | — | — | — | 50.12% | -46.14% | -47.61% | -384.98% | -281.81% | -70.99% | 1.11 | -8.17 | 1.72 | 0.93 | 0.07 | -7527.00% | 949.00% | -5851.00% | — | -0.85 | -169.15% | — | 0.00% | — | — | — | — | — |
| ADIL | Adial Pharmaceuticals, In… | $2.53 | 2.43M | — | — | — | — | -1.06 | 3.43 | — | -1.23 | — | 3.43 | 0.00% | — | — | -323.80% | -1052.66% | -269.86% | 0.00 | — | 4.16 | 3.84 | 0.45 | -8695.00% | — | — | -49.65% | -7.09 | -879.58% | 0.00% | 0.00% | 6.62% | -1.23 | -1.47 | — | -18.87 |
| CHEK | Check-Cap Ltd. | $1.68 | 9.83M | — | — | — | — | -0.19 | -3.24 | — | -0.49 | -0.43 | -3.24 | 0.00% | — | — | -226.19% | 1959.89% | -198.07% | -0.09 | -2883.22 | 0.15 | 0.15 | -0.01 | 4333.00% | — | -9995.00% | -0.17% | 0.00 | 0.60% | 0.00% | 0.00% | 0.00% | -0.18 | -570.68 | — | -861.86 |
| EVOK | Evoke Pharma, Inc. | $11.00 | 18.95M | +308% | +3,860,968% | — | — | -1.38 | 1.05 | 0.72 | 0.22 | — | 1.05 | 96.52% | -50.77% | -52.22% | -240.09% | 280.01% | -43.54% | 0.73 | -10.38 | 1.66 | 1.54 | 1.74 | -8995.00% | 9784.00% | 950.00% | -73.85% | -0.53 | 293.71% | 0.00% | 0.00% | 117.66% | 0.20 | 0.19 | -0.10 | -9.79 |
| HCWB | HCW Biologics Inc. | $0.54 | 1.16M | +6,101% | +980% | — | +51% | -18.86 | -83.66 | 220.66 | -20.79 | -188.64 | -83.66 | 37.38% | -1148.50% | -1169.70% | -897.37% | -320.11% | -102.21% | -2.02 | -25.45 | 0.19 | 0.18 | -0.33 | 1000.00% | -968.00% | -4954.00% | -2.56% | -0.48 | -157.33% | 0.00% | 0.00% | 0.00% | -19.52 | -39.71 | 224.17 | 0.44 |
| IINN | Inspira Technologies Oxy … | $0.58 | 13.97M | — | — | — | — | -1.42 | 3.64 | — | -1121.82 | — | 3.64 | 0.00% | — | — | -219.74% | 7.39% | -127.19% | 0.58 | — | 2.02 | 1.71 | 234.68 | -9994.00% | — | -426.00% | -60.68% | -2.78 | -6254.43% | 0.00% | 0.00% | 0.00% | 1104.79 | -1.31 | — | -8.52 |
| LUCY | Innovative Eyewear, Inc. | $1.12 | 5.12M | +2,253% | +40,227,901% | — | — | -0.81 | 0.69 | 3.84 | 0.16 | — | 0.73 | 13.15% | -484.20% | -474.60% | -106.00% | -557.55% | -96.74% | 0.00 | — | 12.52 | 10.38 | 0.35 | -5904.00% | 4199.00% | 1643.00% | -111.49% | -9.14 | -493.01% | 0.00% | 0.00% | 0.00% | 0.16 | 0.18 | -0.76 | 0.10 |
| SBFM | Sunshine Biopharma, Inc. | $1.20 | 5.89M | +4,340% | +64,945,046% | — | — | -0.33 | 0.07 | 0.05 | 1.37 | — | 0.08 | 30.60% | -16.67% | -14.72% | -22.97% | -54.65% | -17.73% | 0.04 | -662.41 | 4.11 | 2.15 | 1.69 | -9792.00% | 4475.00% | 5530.00% | -885.54% | -1.98 | -146.04% | 0.00% | 0.00% | 187.20% | 1.21 | 0.48 | -0.20 | -1.74 |
| SNOA | Sonoma Pharmaceuticals, I… | $2.90 | 5.02M | +34,823% | -54% | — | — | -1.19 | 0.93 | 0.29 | 0.27 | — | 0.93 | 38.25% | -25.97% | -24.20% | -65.55% | -250.76% | -24.32% | 0.07 | — | 3.09 | 2.23 | 1.42 | -4756.00% | 1219.00% | -9304.00% | -4.08% | -0.02 | -11.36% | 0.00% | 0.00% | 61.89% | 0.26 | 5.65 | -0.07 | -19.06 |
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
- CEO
- Hermann Luebbert
- Employees
- 92
- Beta
- 0.63
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ —) − 1 = — (DCF, example).